RETRACTED: Effects of High Flux Hemodialysis Combined with L-Carnitine on Microinflammation and Arteriovenous Fistula in Maintenance Hemodialysis Patients (Retracted Article)

Objective. To explore the effects of high-flux hemodialysis combined with L-carnitine on microinflammation and arteriovenous fistulas in maintenance hemodialysis patients. Methods. A total of 65 patients admitted to our hospital from May 2017 to May 2019 were selected and divided into a control group of 30 cases and an experimental group of 35 cases according to the selected treatment plan. Combined with L-carnitine, the cardiac function of the two groups of patients before and after the treatment was evaluated, the microinflammatory indexes of the two groups were compared, and the clinical efficacy of the combined treatment on MHD patients was analyzed. Results. The two groups were not significantly different in general information such as age, gender, course of disease, and past medical history (P > 0.05). The experimental group generated a notably higher total effective rate of treatment in relation to the control group (P < 0.05). After treatment, lower heart function levels of LVST and LEVDD were observed in the experimental group as compared to the control group, but LVEF was higher than that in the control group (P < 0.05). The GQOLI-74 score of the experimental group was better than that of the control group (P < 0.05). The incidence of venous fistula complications in the experimental group was significantly lower than that in the control group (P < 0.05). The microinflammatory index hs-CRP in the experimental group was lower (P < 0.05) and the microinflammatory index TNF-alpha was significantly lower (P < 0.05). The HAD score after treatment of the experimental group was better than that of the control group (P < 0.05). Conclusion. High-flux hemodialysis combined with L-carnitine therapy has achieved satisfactory results in patients with MHD in terms of alleviating the level of inflammatory factors, improving heart function, enhancing patients' living standards, reducing complications of intravenous fistula, and boosting the prognosis. It is worthy of promotion.